RUA Medical acquired by AorTech

As part of the deal, AorTech will change its name to RUA Life Sciences PLC and David will become Chief Executive Officer of the enlarged group. RUA Medical will remain a full-service medical device subcontract manufacturer and will continue to serve its existing customers with the same people and facilities, and provide the quality of products and service previously enjoyed.

AorTech owns the IP to the world’s leading long-term implantable biostable polymer  (Elast-Eon™)  and  is  developing  medical  devices utilising  the  key properties  of  Elast-Eon™.  RUA Medical has been a development partner of AorTech and will continue to design, develop and manufacture devices for other companies within the enlarged group including RUA Vascular and RUA Structural Heart.

David Richmond, who takes on a new role as Chief Executive of RUA Life Sciences PLC, will  continue  in  his  Global  Business  Development  role  at  RUA Medical  looking  after  key  customer  relationships  and  new  product  design alongside our growing R&D and engineering teams.

David Richmond said: “This is an exciting opportunity that takes RUA Medical to the next stage of development and will help grow and deepen relationships with both existing and new customers.”

Bill Brown, Chairman of AorTech said: “This deal is a perfect strategic fit for AorTech providing the people, processes and premises to allow our world class polymers to be converted into medical device products.  We look forward to a closer working relationship with David Richmond and his talented team at RUA Medical and are delighted that David has demonstrated his belief and confidence in the prospects for all of our Elast-Eon™ enabled  devices  by  taking  a  substantial  shareholding in  the  enlarged group.”

RUA Medical is an experienced full-service medical device contract developer, contract manufacturer and implantable fabric specialist. RUA Medical provides subcontract design, development, manufacture, assembly, packing, inventory management, logistics and consultancy services to the Medical Device and Biotech Industries.  The company partners with medical device and biotech companies to provide technologically innovative products that can deliver lifesaving and life enhancing solutions, and focuses on personalised service, combined with innovative design and development.

Aortech International PLC, to be renamed as RUA Life Sciences PLC, has developed biostable, implantable  polymers,  including  Elast-Eon™  and  ECSil™  the  world’s  leading long-term implantable  co-polymers,  now  manufactured  on  their  behalf  by  Biomerics LLC  in  Utah, USA. With several  million  implants  and  seven  years  of  successful clinical  use,  these polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from RUA Life Sciences polymers have numerous US FDA PMA approvals, 510k’s, CE Marks, Australian TGA and Japanese Ministry of Health approvals.